PURPOSE:Patients with locally advanced prostate cancer have an increased risk of cancer recurrence and mortality. In this phase II trial, we evaluate neoadjuvant enzalutamide and leuprolide (EL) with or without abiraterone and prednisone (ELAP) before radical prostatectomy (RP) in men with locally advanced prostate cancer. PATIENTS AND METHODS: Eligible patients had a biopsy Gleason score of 4 + 3 = 7 or greater, prostate-specific antigen (PSA) greater than 20 ng/mL, or T3 disease (by prostate magnetic resonance imaging). Lymph nodes were required to be smaller than 20 mm. Patients were randomly assigned 2:1 to ELAP or EL for 24 weeks followed by RP. All specimens underwent central pathology review. The primary end point was pathologic complete response or minimal residual disease (residual tumor ≤ 5 mm). Secondary end points were PSA, surgical staging, positive margins, and safety. Biomarkers associated with pathologic outcomes were explored. RESULTS:Seventy-five patients were enrolled at four centers. Most patients had high-risk disease by National Comprehensive Cancer Network criteria (n = 65; 87%). The pathologic complete response or minimal residual disease rate was 30% (n = 15 of 50) in ELAP-treated patients and 16% (n = four of 25) in EL-treated patients (two-sided P = .263). Rates of ypT3 disease, positive margins, and positive lymph nodes were similar between arms. Treatment was well-tolerated. Residual tumors in the two arms showed comparable levels of ERG, PTEN, androgen receptor PSA, and glucocorticoid receptor expression. Tumor ERG positivity and PTEN loss were associated with more extensive residual tumors at RP. CONCLUSION:Neoadjuvant hormone therapy followed by RP in locally advanced prostate cancer resulted in favorable pathologic responses in some patients, with a trend toward improved pathologic outcomes with ELAP. Longer follow-up is necessary to evaluate the impact of therapy on recurrence rates. The potential association of ERG and PTEN alterations with worse outcomes warrants additional investigation.
RCT Entities:
PURPOSE:Patients with locally advanced prostate cancer have an increased risk of cancer recurrence and mortality. In this phase II trial, we evaluate neoadjuvant enzalutamide and leuprolide (EL) with or without abiraterone and prednisone (ELAP) before radical prostatectomy (RP) in men with locally advanced prostate cancer. PATIENTS AND METHODS: Eligible patients had a biopsy Gleason score of 4 + 3 = 7 or greater, prostate-specific antigen (PSA) greater than 20 ng/mL, or T3 disease (by prostate magnetic resonance imaging). Lymph nodes were required to be smaller than 20 mm. Patients were randomly assigned 2:1 to ELAP or EL for 24 weeks followed by RP. All specimens underwent central pathology review. The primary end point was pathologic complete response or minimal residual disease (residual tumor ≤ 5 mm). Secondary end points were PSA, surgical staging, positive margins, and safety. Biomarkers associated with pathologic outcomes were explored. RESULTS: Seventy-five patients were enrolled at four centers. Most patients had high-risk disease by National Comprehensive Cancer Network criteria (n = 65; 87%). The pathologic complete response or minimal residual disease rate was 30% (n = 15 of 50) in ELAP-treated patients and 16% (n = four of 25) in EL-treated patients (two-sided P = .263). Rates of ypT3 disease, positive margins, and positive lymph nodes were similar between arms. Treatment was well-tolerated. Residual tumors in the two arms showed comparable levels of ERG, PTEN, androgen receptor PSA, and glucocorticoid receptor expression. TumorERG positivity and PTEN loss were associated with more extensive residual tumors at RP. CONCLUSION: Neoadjuvant hormone therapy followed by RP in locally advanced prostate cancer resulted in favorable pathologic responses in some patients, with a trend toward improved pathologic outcomes with ELAP. Longer follow-up is necessary to evaluate the impact of therapy on recurrence rates. The potential association of ERG and PTEN alterations with worse outcomes warrants additional investigation.
Authors: Bimal Bhindi; R Jeffrey Karnes; Laureano J Rangel; Ross J Mason; Matthew T Gettman; Igor Frank; Matthew K Tollefson; Daniel W Lin; R Houston Thompson; Stephen A Boorjian Journal: J Urol Date: 2017-06-29 Impact factor: 7.450
Authors: Nicola J Clegg; John Wongvipat; James D Joseph; Chris Tran; Samedy Ouk; Anna Dilhas; Yu Chen; Kate Grillot; Eric D Bischoff; Ling Cai; Anna Aparicio; Steven Dorow; Vivek Arora; Gang Shao; Jing Qian; Hong Zhao; Guangbin Yang; Chunyan Cao; John Sensintaffar; Teresa Wasielewska; Mark R Herbert; Celine Bonnefous; Beatrice Darimont; Howard I Scher; Peter Smith-Jones; Mark Klang; Nicholas D Smith; Elisa De Stanchina; Nian Wu; Ouathek Ouerfelli; Peter J Rix; Richard A Heyman; Michael E Jung; Charles L Sawyers; Jeffrey H Hager Journal: Cancer Res Date: 2012-01-20 Impact factor: 12.701
Authors: Masis Isikbay; Kristen Otto; Steven Kregel; Jacob Kach; Yi Cai; Donald J Vander Griend; Suzanne D Conzen; Russell Z Szmulewitz Journal: Horm Cancer Date: 2014-03-11 Impact factor: 3.869
Authors: Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Andrea Sboner; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan Journal: Cell Date: 2015-07-16 Impact factor: 41.582
Authors: Scott E Eggener; Peter T Scardino; Patrick C Walsh; Misop Han; Alan W Partin; Bruce J Trock; Zhaoyong Feng; David P Wood; James A Eastham; Ofer Yossepowitch; Danny M Rabah; Michael W Kattan; Changhong Yu; Eric A Klein; Andrew J Stephenson Journal: J Urol Date: 2011-01-15 Impact factor: 7.450
Authors: Adam G Sowalsky; Huihui Ye; Manoj Bhasin; Eliezer M Van Allen; Massimo Loda; Rosina T Lis; Laleh Montaser-Kouhsari; Carla Calagua; Fen Ma; Joshua W Russo; Rachel J Schaefer; Olga S Voznesensky; Zhenwei Zhang; Glenn J Bubley; Bruce Montgomery; Elahe A Mostaghel; Peter S Nelson; Mary-Ellen Taplin; Steven P Balk Journal: Cancer Res Date: 2018-06-19 Impact factor: 12.701
Authors: Adam C Berger; Jeffrey Farma; Walter J Scott; Gary Freedman; Louis Weiner; Jonathan D Cheng; Hao Wang; Melvyn Goldberg Journal: J Clin Oncol Date: 2005-03-21 Impact factor: 44.544
Authors: W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai Journal: J Clin Oncol Date: 2007-09-04 Impact factor: 44.544
Authors: Wanling Xie; Meredith M Regan; Marc Buyse; Susan Halabi; Philip W Kantoff; Oliver Sartor; Howard Soule; Noel W Clarke; Laurence Collette; James J Dignam; Karim Fizazi; Wendy R Paruleker; Howard M Sandler; Matthew R Sydes; Bertrand Tombal; Scott G Williams; Christopher J Sweeney Journal: J Clin Oncol Date: 2017-08-10 Impact factor: 44.544
Authors: Scott Wilkinson; Huihui Ye; Fatima Karzai; Stephanie A Harmon; Nicholas T Terrigino; David J VanderWeele; John R Bright; Rayann Atway; Shana Y Trostel; Nicole V Carrabba; Nichelle C Whitlock; Stephanie M Walker; Rosina T Lis; Houssein Abdul Sater; Brian J Capaldo; Ravi A Madan; James L Gulley; Guinevere Chun; Maria J Merino; Peter A Pinto; Daniela C Salles; Harsimar B Kaur; Tamara L Lotan; David J Venzon; Peter L Choyke; Baris Turkbey; William L Dahut; Adam G Sowalsky Journal: Eur Urol Date: 2021-03-27 Impact factor: 20.096
Authors: Weranja Ranasinghe; Daniel D Shapiro; Miao Zhang; Tharakeswara Bathala; Nora Navone; Timothy C Thompson; Bradley Broom; Ana Aparicio; Shi-Ming Tu; Chad Tang; John W Davis; Louis Pisters; Brian F Chapin Journal: Nat Rev Urol Date: 2021-04-06 Impact factor: 14.432
Authors: Laura S Graham; Lawrence D True; Roman Gulati; George R Schade; Jonathan Wright; Petros Grivas; Todd Yezefski; Katie Nega; Katerina Alexander; Wen-Min Hou; Evan Y Yu; Bruce Montgomery; Elahe A Mostaghel; Alvin A Matsumoto; Brett Marck; Nima Sharifi; William J Ellis; Nicholas P Reder; Daniel W Lin; Peter S Nelson; Michael T Schweizer Journal: Prostate Date: 2021-03-23 Impact factor: 4.104
Authors: James A Eastham; Glenn Heller; Susan Halabi; J Paul Monk; Himisha Beltran; Martin Gleave; Christopher P Evans; Steven K Clinton; Russell Z Szmulewitz; Jonathan Coleman; David W Hillman; Colleen R Watt; Saby George; Martin G Sanda; Olwen M Hahn; Mary-Ellen Taplin; J Kellogg Parsons; James L Mohler; Eric J Small; Michael J Morris Journal: J Clin Oncol Date: 2020-07-24 Impact factor: 44.544
Authors: Marek Cmero; Natalie J Kurganovs; Ryan Stuchbery; Patrick McCoy; Corrina Grima; Anne Ngyuen; Ken Chow; Stefano Mangiola; Geoff Macintyre; Nicholas Howard; Michael Kerger; Philip Dundee; Paul Ruljancich; David Clarke; Jeremy Grummet; Justin S Peters; Anthony J Costello; Sam Norden; Andrew Ryan; Phillip Parente; Christopher M Hovens; Niall M Corcoran Journal: JCO Precis Oncol Date: 2021-06-22
Authors: Daniel E Spratt; Neal Shore; Oliver Sartor; Dana Rathkopf; Kara Olivier Journal: Prostate Cancer Prostatic Dis Date: 2021-02-18 Impact factor: 5.554